Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
Kazumasa YamamotoShun YamamotoKen KatoPublished in: Expert opinion on drug safety (2024)
Pembrolizumab-containing therapies are tolerable as first- and second-line treatments in patients with advanced ESCC. Although infrequent, immune-related adverse events may occur in patients on pembrolizumab-containing therapies. These events are potentially fatal and require treatment with steroids or immunosuppressive drugs. Regular physical and laboratory examinations, including measurement of hormone levels, are needed during and after pembrolizumab-containing therapies in clinical practice.
Keyphrases
- squamous cell carcinoma
- advanced non small cell lung cancer
- locally advanced
- end stage renal disease
- clinical practice
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- rectal cancer
- neoadjuvant chemotherapy
- prognostic factors
- mental health
- radiation therapy
- peritoneal dialysis
- epidermal growth factor receptor
- lymph node metastasis
- lymph node
- study protocol
- clinical evaluation